The University of Southampton
University of Southampton Institutional Repository

Immunotherapy of myeloid leukaemias

Immunotherapy of myeloid leukaemias
Immunotherapy of myeloid leukaemias
The treatment of myeloid leukaemia has progressed in recent years with the advent of donor leukocyte infusions (DLI), haemopoietic stem cell transplants (HSCTs) and targeted therapies. However, relapse has a high associated morbidity rate and a method for removing diseased cells in first remission, when a minimal residual disease state is achieved and tumour load is low, has the potential to extend remission times and prevent relapse especially when used in combination with conventional treatments. Acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are heterogeneous diseases which lack one common molecular target while chronic myeloid leukaemia (CML) patients have experienced prolonged remissions through the use of targeted therapies which remove BCR-ABL(+) cells effectively in early chronic phase. However, escape mutants have arisen and this therapy has little effectivity in the late chronic phase. Here we review the immune therapies which are close to or in clinical trials for the myeloid leukaemias and describe their potential advantages and disadvantages
myeloid leukaemia, immunotherapy, tumour associated antigens, cancer-testis antigens, SEREX, cDNA microarray
0340-7004
943-957
Guinn, Barbara-Ann
728d28c9-a23d-413a-ba1d-4531005705d7
Mohamedali, Azim
bf5195ae-fe4f-43d7-9dc5-222d2e5776d3
Thomas, N.Shaun B.
0cd2fbef-b152-4ff5-a1bc-a4c7818c00be
Mills, Ken I.
be9c4b93-fda3-40b1-8514-9191652ab8b7
Guinn, Barbara-Ann
728d28c9-a23d-413a-ba1d-4531005705d7
Mohamedali, Azim
bf5195ae-fe4f-43d7-9dc5-222d2e5776d3
Thomas, N.Shaun B.
0cd2fbef-b152-4ff5-a1bc-a4c7818c00be
Mills, Ken I.
be9c4b93-fda3-40b1-8514-9191652ab8b7

Guinn, Barbara-Ann, Mohamedali, Azim, Thomas, N.Shaun B. and Mills, Ken I. (2006) Immunotherapy of myeloid leukaemias. Cancer Immunology Immunotherapy, 56 (7), 943-957. (doi:10.1007/s00262-006-0267-y).

Record type: Article

Abstract

The treatment of myeloid leukaemia has progressed in recent years with the advent of donor leukocyte infusions (DLI), haemopoietic stem cell transplants (HSCTs) and targeted therapies. However, relapse has a high associated morbidity rate and a method for removing diseased cells in first remission, when a minimal residual disease state is achieved and tumour load is low, has the potential to extend remission times and prevent relapse especially when used in combination with conventional treatments. Acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) are heterogeneous diseases which lack one common molecular target while chronic myeloid leukaemia (CML) patients have experienced prolonged remissions through the use of targeted therapies which remove BCR-ABL(+) cells effectively in early chronic phase. However, escape mutants have arisen and this therapy has little effectivity in the late chronic phase. Here we review the immune therapies which are close to or in clinical trials for the myeloid leukaemias and describe their potential advantages and disadvantages

Full text not available from this repository.

More information

Published date: 20 December 2006
Keywords: myeloid leukaemia, immunotherapy, tumour associated antigens, cancer-testis antigens, SEREX, cDNA microarray

Identifiers

Local EPrints ID: 71568
URI: http://eprints.soton.ac.uk/id/eprint/71568
ISSN: 0340-7004
PURE UUID: 8b2fb3eb-ce41-4c54-be48-f151d9342344

Catalogue record

Date deposited: 14 Dec 2009
Last modified: 19 Jul 2019 23:44

Export record

Altmetrics

Contributors

Author: Barbara-Ann Guinn
Author: Azim Mohamedali
Author: N.Shaun B. Thomas
Author: Ken I. Mills

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×